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Abstract. The anxiolytic activity of methylclonazepam was 
compared to lorazepam and placebo in a double-blind, ran- 
domized cross-over study, using a latin square design, in 
18 inpatients meeting Research Diagnostic Criteria for 
Generalized Anxiety Disorders. Patients presented at least 
1 year of symptomatology and had a minimum score of 
20 on the Hamilton Anxiety Scale, despite chronic anxio- 
lyric pharmacotherapy. Daily dosage was flexible, from 
three to six tablets of methylclonazepam 1 rag, lorazepam 
2.5 rag, or placebo. Clinical evaluation included Hamilton 
Anxiety Scale, Clinical Global Impression (CGI), a side- 
effects checklist, completed every 2 days, and the global 
preference of the patient for one of the treatment periods. 
Results showed a highly significant superiority of both 
benzodiazepines over placebo on the Hamilton Scale (P< 
0.00001) and CGI (P<  0.001), and also a significant superi- 
ority of methylclonazepam over lorazepam on the Hamilton 
Scale (P<0.01), CGI-1 (P<0.01), and in the number of 
patient preferences (14 versus 1 ; P <  0.001), with no signifi- 
cant differences in side-effects or related to position in the 
trial. These results support the value of the cross-over de- 
sign in chronic and severe anxious inpatients for the demon- 
stration of differences in efficacy between anxiolytic phar- 
macotherapies. 
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The synthesis of the benzodiazepine structure has repre- 
sented a major breakthrough in the pharmacological treat- 
ment of anxiety disorders (Sternbach 1983). Following the 
introduction of chlordiazepoxide in 1960, numerous com- 
pounds have been marketed, differing in their potency and 
pharmacokinetic properties (Greenblatt et al. 1983 a). Con- 
troversy still exists, however, with respect to the more subtle 
clinical differences which seem to exist among compounds 
(Baskin and Esdale 1982; Greenblatt et al. 1983 b; Lapierre 
1983; Chouinard et al. 1983; Straw 1983). As a group, the 
benzodiazepines are clearly superior in anxiolytic activity 
to the other classes of antianxiety agents and are much 
less toxic at clinically useful doses (Rickels 1983). However, 
the marketed compounds do not consistently provide spe- 
cific or definitive therapy for the exceedingly complex and 
variable clinical syndrome of anxiety, suggesting the need 
to develop more active derivatives (Goldberg 1984). In this 
context, the synthesis of methylclonazepam, a new long 
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Fig. 1. Structural formula of methylclonazepam 
plasma half-life (40 h) benzodiazepine (Fig. 1), could repre- 
sent an improvement. Indeed, animal data showed that 
methyMonazepam was far more potent that diazepam in 
tests predictive of anxiolytic activity (~-3 x in the conflict 
test in rats), and in the in vitro as well as in vivo benzodiaze- 
pine binding assay. The in vivo potency of methylclonaze- 
pam is similar to that of flunitrazepam (EDso =0.3 mg/kg 
po), the most potent benzodiazepine tested to date (M6hler 
and Richards 1983). Moreover, in an open trial, we found 
that 7 of 12 chronic anxious inpatients, who had not re- 
sponded well to large doses of standard benzodiazepines 
(essentially lorazepam, bromazepam, or diazepam), 
strongly preferred methylclonazepam therapy (Ansseau 
et al. unpublished). The purpose of the present study was, 
therefore, to assess more rigourously the possible anxiolytic 
superiority of methylclonazepam over current benzodiaze- 
pine compounds, using a double-blind cross-over design, 
with randomization of three treatments: methylclonaze- 
pare, lorazepam (the current most potent anxiolytic com- 
pound), and placebo, in a selected group of chronic anxious 
inpatients. As will be discussed, we feel that the cross-over 
design offers greater power in comparative efficacy studies. 
Subjects and methods 
Subjects. The study was performed in the Psychopharmaco- 
logy Unit of the University Hospital of Liege, Belgium. 
The sample consisted of 18 newly admitted inpatients meet- 
ing Research Diagnostic Criteria (RDC) (Spitzer et al. 
1978) for "Generalized Anxiety Disorder", as determined 
by two independent research psychiatrists using semi-stan- 
dardized clinical interviews. In addition, subjects had to 
present: 1) chronic and steady symptomatology, with a 
minimum 1-year history of regular daily intake of high 
doses of tranquillizers (at least 30 mg diazepam or equiva- 
lent); and 2) a high level of severity (minimum of 20 on 
the Hamilton Anxiety Scale) (Hamilton 1959), despite their 
anxiolytic treatment. We excluded patients with a pre-ex- 
isting or concurrent RDC diagnosis of major and minor 
Table l. Demographical and clinical characteristics of the sample 
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# Sex Age Illness Current Current Concurrent 
duration episode anxiolytic Hamilton 
(years) duration treatment anxiety 
(years) (daily dose in nag) score 
t M 53 26 5 Bromazepana 36 35 
2 M 46 3 3 Diazepam 60 28 
3 M 48 3 3 Diazepana 40 32 
Propanolol 60 
4 F 51 11 2 Bronaazepam 36 27 
Lormetazepam 2 
5 M 48 16 7 Diazepana 30 35 
Flunitrazepana 2 
6 F 58 10 1 Oxazepam 75 27 
Doxepin 150 
7 F 50 2 2 Diazepam 15 35 
Bronaazepam 15 
8 M 66 14 14 Diazepana 20 33 
Doxepin 75 
9 F 35 4 4 Bromazepana 18 36 
Mianserin 90 
10 F 41 2 2 Bromazepam 24 30 
Sulpiride 150 
11 M 57 11 11 Bronaazepana 36 31 
Levomepromazine 45 
Mianserin 60 
12 F 32 3 3 Prazepana 40 27 
Ketazolana 30 
Propanolol 60 
13 M 42 22 3 Prazepam 60 28 
Mianserin 60 
14 F 47 2 2 Bromazepana 24 30 
Ketazolam 30 
Propanolol 30 
15 M 51 16 3 Diazepana 30 28 
Levomepromazine 30 
Doxepin 150 
16 M 47 3 3 Bronaazepana 18 
Oxazepana 150 
17 M 39 13 2 Diazepana 30 26 
Ketazolana 30 
18 M 23 2 2 Prazepam 60 29 
Propanolol 120 
Doxepin 75 
Mean 46.3 9.1 4 30.4 
(SD) (10.1 ) (7.6) (3.4) (3.3) 
Sex distribution I 1 M, 7 F 
depressive disorders,  phobic  disorder,  obsessive compulsive 
disorder,  alcoholism, or  drug use disorder,  a l ready treated 
with lorazepam, or presenting evidence of  medical illness 
on history, physical  examinat ion,  EKG,  chest X-ray, EEG,  
and routine l abora to ry  tests, and, pr ior  to par t ic ipat ion,  
all subjects gave informed consent. 
The demographical  and clinical characteristics of  the 
sample are displayed in Table 1. All  patients were hospita-  
lized due to the high level of  their anxious symptomatology,  
which significantly interferred with their familial, profes- 
sional, and social functioning, and their poor  response to 
previous pharmacologica l  or  psychological  interventions. 
Design of the study. The study compared  methylclonaze- 
pam, lorazepam, and placebo according to a double-blind,  
cross-over design, with flexible dosage. The order  of  treat-  
ments was randomized according to a latin square design. 
Methylc lonazepam (1 mg), lorazepam (2.5 mg), and pla- 
cebo were presented as tablets of  the same appearance,  indi- 
vidually prepared  in three different bottles (A, B, and C), 
according to each randomized order  of  treatments.  The 
t reatment  was always administered in three daily intakes 
(7 A.M., 12 noon,  and 10 P.M.), since we have previously 
demonstra ted greater efficacy of  divided doses of  a long 
half-life benzodiazepine over a single evening intake in se- 
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verely anxious inpatients (Ansseau et al. 1984b). During 
each phase, the initial dose was three tablets daily (i.e. meth- 
ylclonazepam 3 rag, lorazepam 7.5 rag, or placebo) and 
could be increased in increments of 1/2 tablet every other 
day to a daily maximum of six tablets; however, the increase 
could be more rapid in obvious worsening of the symptoma- 
tology. The final maintenance dosage lasted 4 days, before 
the beginning of the following phase or the termination 
of the study, but could be reduced to 2 days in complete 
therapeutic failure. There was no wash-out period before 
the beginning of the trial nor between consecutive phases. 
No other psychotropic medication was allowed throughout 
the study. 
Psychometric assessment. The patients' clinical condition 
was assessed before treatment and every 2 days throughout 
the study by means of the Hamilton Anxiety Scale (Hamil- 
ton 1959), the Clinical Global Impression (CGI) (Guy 
1976), and a side-effects checklist. At the end of the study, 
the patient was asked to select which of the three treatments 
he or she preferred - would like to continue - according 
to both efficacy and tolerance. 
Data analysis. Since patients exhibited chronic and stable 
condition, and since no wash-out period was included be- 
tween drug periods, final scores of each period (representing 
optimal results with the compounds) were compared using 
variance analysis (ANOVA) with repeated measures, first 
including the three periods and then comparing methylclon- 
azepam with lorazepam. Patients were also divided into 
six subgroups according to their treatment sequences in 
order to assess a possible influence of the order of treatment 
on the therapeutic result (sequence effect and sequence-drug 
interaction). The distribution of patients' preferences was 
analyzed using the sign test, often referred to in this context 
as McNemar's test (Hills and Armitage 1979); and in order 
to eliminate a possible influence of the position in the trial 
on patients' preferences, the distribution of preferred period 
(A, B, or C) was analysed in the same way. Finally, the 
results of the study were also analyzed as a parallel group 
trial, using only the first treatment period, in order to com- 
pare the power of cross-over and parallel group designs 
in detecting differences in therapeutic efficacy. 
Results 
Dosages and duration of treatment phases. Mean end of peri- 
od dosages (SD) were: methylclonazepam 5.1 nag (0.4), lor- 
azepam 13.8 mg (2.0) and placebo 5.9 tablets (0.2). The 
mean optimal dosages (SD) corresponding to patients' pref- 
erences (including equalities of judgement) were methyl- 
clonazepam (n=16) 4.9 nag (0.7), and lorazepam (n=5) 
13.2 mg (1.8). 
Duration of treatment phases ranged from 8 to 18 days 
for methylclonazepam (mean__ SD = 15.4 • 2.4); from 4 to 
18 days for lorazepam (mean_+ SD = 14.5 +_ 4.0); and from 
4 to 18 days for placebo (mean+_ SD =8.1 +4.3), indicating 
a significantly shorter period on placebo than on active 
drugs [F(2, 34)= 17.06; P<0.001], but no differences be- 
tween the benzodiazepines IF(l, 17) = 2.26; NS]. 
Hamilton anxiety scale. Individual final scores and changes 
over time on the Hamilton Anxiety Scale during each of 
the three treatments are displayed in Table 2 and Fig. 2. 
Mean scores (SD) at the end of each period were 12.3 (8.5) 
after methylclonazepam, 17.3 (7.8) after lorazepam, and 
28.2 (9.1) after placebo. These results showed a significant 
superiority of both active drugs over placebo [F(2, 
24)=31.83; P<0.00001] and of methylclonazepam over 
lorazepam [F(1, 12)=9.93; P<0.01]. The distribution of 
patients into six subgroups according to their treatment 
orders showed no sequence effect (P=0.93) and no se- 
quence-drug interaction (P = 0.81). 
When analyzed as a double-blind parallel study using 
only the first period, mean final scores (SD) were 12.0 (9.4) 
for methylclonazepam, 19.5 (7.3) for lorazepam, and 29.3 
(6.0) for placebo, showing a clear superiority of both benzo- 
diazepines over placebo [F(I, 21)= 9.95; P <  0.01], but no 
difference between active drugs [F(1, 10)= 0.48; NS]. 
CGL Individual CGI scores at the end of each treatment 
period are presented in Table 2. Mean CGI (SD) of illness 
severity was 3.17 (1.29) at the end of methylclonazepam 
treatment, 4.17 (1.10) at the end of lorazepam treatment, 
and 5.61 (1.38) at the end of placebo period, indicating 
a significant superiority of active drugs over placebo [F(2, 
34) = 15.02; P < 0.001] and of methylclonazepam over lora- 
zepam [F(1, 17)=9.00; P<0.01]. Final CGI ratings of 
global improvement (SD) were, respectively, 1.89 (0.83), 
3.06 (3.06), and 5.00 (2.03) for methylclonazepam, loraze- 
pam, and placebo, also showing significantly better efficacy 
of both benzodiazepines over placebo [F(2, 34) = 14.98 ; P < 
0.001] and a trend towards superiority of methylclonaze- 
pare over lorazepam [F(I, 17) = 4.14; P = 0.06]. Mean effi- 
cacy indexes (SD) were 3.00 (0.95) for the methylclonazepam 
period, 2.39 (1.00) fbr the lorazepam period, and 1.55 (0.86) 
for the placebo period, indicating a superiority of active 
compounds over placebo 0f 2 = 7.80, df= 2; P < 0.001), with- 
out significant differences between benzodiazepines. 
Patients' preferences. At the end of the study, 11 patients 
(61.1%) chose methylclonazepam as best treatment, one 
chose lorazepam, four (22.2%) preferred both active com- 
pounds without differentiating between them, one preferred 
both methylclonazepam and placebo over lorazepam, and 
one experienced a equal complete therapeutic failure with 
all three treatments (Table 2). These results showed a clear 
statistical superiority of active drugs over placebo (P< 
0.0001) and of methylclonazepam over lorazepam (P<  
0.001). The preferences in favor of methylclonazepam were 
based on a better activity (n = 9) and on both greater effi- 
cacy and tolerance (n =2);  the preference for lorazepam 
was based on better efficacy (n = 1). According to the posi- 
tion in the trial, the 12 periods selected were five periods 
A (41.7%), four periods B (33.3%) and three periods C 
(25%), indicating absence of significant influence of posi- 
tion on preference. 
Side-effects. Three patients experienced side-effects during 
methyMonazepam therapy [drowsiness (n = 1), fatigue (n = 
1), and dry mouth (n=l) ] ;  five during lorazepam therapy 
[drowsiness (n=3), ataxia (n=2), shaking ( n = l ) ,  dry 
mouth (n=l ) ,  and constipation (n=l)] ;  and one during 
placebo period [fatigue (n= 1)] (no significant difference). 
No differences in reported side-effects appeared according 
to the position in the trial: three during period A, five 
during period B, and three during period C. 
Table 2. Results 
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Patient Final Hamilton Final CGI-1 Final CGI-2 Final CGI-3 
4+ 
MC L PI MC L P1 MC L PI MC L P1 
Preference 
I 18 19 29 5 5 6 2 2 4 06 06 13 M C + L  
2 18 25 41 3 4 7 1 2 6 05 05 13 MC 
3 18 15 31 5 5 7 2 2 4 05 05 13 L 
4 5 6 12 2 2 3 3 3 3 01 0J 05 M C + L  
5 10 16 28 4 5 6 2 2 3 06 06 10 MC 
6 34 27 33 6 4 5 4 2 4 13 08 13 0 
7 28 37 44 4 5 7 3 4 6 09 15 13 MC 
8 2 11 23 1 4 5 1 2 3 01 05 09 MC 
9 12 10 36 3 3 6 2 2 4 05 05 13 MC+ L 
10 12 17 29 3 4 6 2 2 4 05 05 13 MC 
11 4 14 28 2 4 6 1 2 4 01 05 13 MC 
12 15 23 32 4 6 7 2 3 4 05 09 13 MC 
13 9 14 22 3 4 5 2 2 3 05 05 09 MC 
14 6 11 26 2 3 5 1 2 3 01 05 09 MC 
15 10 11 33 3 3 7 2 2 5 05 05 13 M C + L  
16 4 26 5 2 6 2 1 4 1 01 13 01 MC+P1 
17 6 20 31 2 5 6 1 3 5 01 09 13 MC 
18 11 10 24 3 3 5 2 2 3 05 05 09 MC 
Mean 12.3 17.3 28.2 3.17 4.17 5.61 1.89 3.06 5.00 3.00 2.39 1.55 
SD 8.5 7.8 9.1 1.29 1.10 1.38 0.83 3.06 2.03 0.95 1.00 0.86 
MC = methylclonazepam; L = lorazepam; P1 = placebo 
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Fig. 2. Changes in Hamilton anxiety scores (mean and standard 
deviation) during treatment with methylclonazepam, lorazepam, 
and placebo, together with number of subjects in each treatment 
cell over time. (Endpoint scores were used for following evaluations 
in periods lasting less than 18 days) 
Discussion 
This study shows not  only clear anxioIytic superiority of  
two benzodiazepine compounds  over placebo,  but  also su- 
periori ty of  the new compound,  methylclonazepam, over 
a s tandard  benzodiazepine,  lorazepam, as measured by the 
Hami l ton  and C G I  scales, and as indicated by pat ient  pref- 
erences. 
With  regard to the superiori ty of  the benzodiazepines 
over placebo demonst ra ted  in this trial, one may argue that  
the periods of  active t reatment  lasted much longer than 
periods for which patients were taking placebo. This may 
give a longer period o f  t ime for the active drugs to work  
and therefore the difference might  be due to a longer expo- 
sure to something that  is actually no more  powerful.  How- 
ever, it should be kept in mind that  the discontinuat ion 
of  a t reatment  per iod was decided according to the clinical 
evolution, and that  the shorter dura t ion of  the placebo peri- 
od reflects the complete ineffectiveness of  placebo in this 
group of  severe and chronically anxious inpatients.  
Concerning the better anxiolytic activity of  methylclon- 
azepam compared  to lorazepam in the present study, the 
possible superiori ty of  any benzodiazepine over another  is 
currently disputed. Many  authors  argue for a therapeutic 
equivalence among all compounds  marketed,  based upon:  
1) the potency of  the compound;  2) pharmacokinet ics  (ab- 
sorption, half-life, active metaboli tes);  and 3) the absence 
of  demonst ra ted  clinical differences (Kesson et al. 1976; Ed- 
i torial  1977; Sellers 1978; Hollister 1978; Editorial  1978; 
Bellantuono et al. 1980; Lader  and Petursson 1983). This 
state of  affairs has led some cost-conscious hospital  formu- 
lary committees to conclude that  all needs can be adequate-  
ly met if  one or possibly two benzodiazepines are made 
available (Greenblat t  et al. 1983 b). 
In fact, however, the lack of  demonst ra ted  clinical dif- 
ferences may  proceed in large par t  from the methodology 
generally used in comparat ive  drug studies. Thus, most  clin- 
ical trials compar ing  benzodiazepines have been performed 
in anxious outpatients,  not  selected with precise criteria, 
and suffering from only a modera te  level o f  anxiety. In 
such subjects, the placebo effects is high (Rickels et al. 
1971); spontaneous remission of  the clinical picture is often 
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present; non-pharmacological factors, which are impossible 
to control, play an important role; and patient compliance 
(i.e. treatment adherence) is problematical. Indeed, some 
patients will return to their former anxiolytics (sometimes 
without the investigator's knowledge) before an adequate 
trial of the prescribed treatment is completed. Moreover, 
these trials generally include small samples of patients, use 
parallel rather than cross-over designs, and last not longer 
than 3 or 4 weeks (Solomon and Hart 1978). Therefore, 
it is not surprising that the resultant coefficient of variation 
is very high and has led to the general conclusion of a 
lack of clinical differences among benzodiazepine com- 
pounds. Moreover, those studies also failed to demonstrate 
clinical differences between benzodiazepines and barbitu- 
rates (thus the preference for benzodiazepines over barbitu- 
rates is based essentially on a lower toxicity), and even 
of benzodiazepines over placebo in nearly half of the pub- 
lished reports (Kellner et al. 1978). 
Many factors can improve the sensitivity and power 
of comparative studies of benzodiazepines. First, the use 
of strict, well-operationalized criteria (such as RDC in the 
present study) increases the homogeneity of the sample (So- 
lomon and Hart 1978); secondly, the selection of patients 
with a sufficient duration of illness (at least 1 year in the 
current trial) ensures that the patients' condition is suffi- 
ciently steady that a spontaneous remission is improbable. 
With similar methodological refinements (i.e. the use of 
DSM-III criteria and a duration of illness of at least 
6 months), Fontaine et al. (1983) were able to show a clear 
superiority of bromazepam over diazepam in two parallel 
groups of 24 patients suffering from generalized anxiety. 
However, the dosages of bromazepam (18 mg/day) and dia- 
zepam (20 rag/day) remained unchanged throughout the 
4-week trial, and it can be argued that the apparent superi- 
ority of bromazepam reflects only proportionately higher 
dosage, as suggested by the higher rate of sedative side- 
effects in the bromazepam-treated group. 
Another methodological refinement is to treat inpa-. 
tients, with a definite level of severity (at least 20 on the 
Hamilton Anxiety Scale, despite anxiolytic pharmacother- 
apy in the current study), rather than outpatients (Ansseau 
et al. 1984a). An inpatient setting allows for more precise 
control of the non-pharmacological factors (most of them 
remaining constant) and facilitates treatment adherence. 
Moreover, the drop-out rate is generally very low in inpa- 
tient studies (none in the present study), and reasons for 
patient attrition can always be analyzed, whereas the drop- 
out rate is generally reported between 25 and 50 percent 
in outpatients (Blackwell 1976), for reasons that often re- 
main unknown. With such methodology, we were able to 
show a clear superiority of prazepam administered in three 
daily divided doses over a single evening intake in inpatients 
with generalized anxiety (Ansseau et al. 1984b, c). 
Probably the most important methodological refine- 
ment is the use of a cross-over trial design, in which the 
effects of different treatments are compared in the s a m e  
subject during successive periods (Hills and Armitage 1979; 
Solomon and Hart 1978; Kellner et al. 1978; Ansseau et al. 
1984a; Uhlenhuth et al. 1979). Such trials are particularly 
suitable for the evaluation of anxiolytics, which alleviate 
the symptoms rather than cure, so that, after the first treat- 
ment, the patient is in a position to receive a second one 
(Hills and Armitage 1979; Solomon and Hart  1978; Bobon 
et al. 1962). However, to avoid a possible influence of the 
sequence of different treatments, the order of the periods 
needs to be randomized and counterbalanced (i.e. balance 
between treatments and order ensured) (Kellner et al. 1978). 
Cross-over trials of benzodiazepines are substantially more 
powerful than parallel groups designs: thus, in comparison 
with placebo, 31 of 39 cross-over comparisons (79%) pub- 
lished to date have shown a significant superiority of the 
benzodiazepines, while only 33 of 58 parallel group studies 
(57%) have demonstrated significant drug-placebo differ- 
ence (Kellner et al. 1978). The greater power of cross-over 
studies is demonstrated even in trials with fewer than 20 pa- 
tients, which also have a larger proportion of positive than 
negative results, whereas comparable results are not reached 
by parallel group studies unless they include more than 
60 patients (Kellner et al. 1978). A cross-over design en- 
abled Deberdt (1974) and Sonne and Holm (1975) to show 
a superiority of bromazepam over diazepam with respect 
to patients' preferences, whereas the use of parallel groups 
failed to show any such difference. The same conclusion 
can be applied to the current study: whereas the cross-over 
design shows a significant superiority of methylclonazepam 
over lorazepam, analysis of the same data as parallel groups 
using the first treatment period is inconclusive. 
However, many statisticians stress the pitfalls of cross- 
over trials: contamination of results of treatment in differ- 
ent periods, particularly if no wash-out period is included 
(as in the present trial) and the difficulty, particularly when 
patients are not in hospital, that any loss of information 
means that the entire data set may be un-analysable. It 
should be noted, however, that no evidence of carry-over 
effect has ever been demonstrated for anxiolytic agents 
(Kellner et al. 1978), a conclusion which is supported by 
the lack of sequence effect and of sequence-drug interaction 
in the present trial. However, the small size of the sample 
cannot exclude that the nonsignificant findings may be due 
to a lack of power of the tests rather than to the absence 
of true interactions. 
The question may also arise of the clinical significance 
of a difference of five points in the final Hamilton score 
between two benzodiazepines, even if this difference is stat- 
istically significant. In fact, taken in isolation, these results 
may have few clinical implications. However, the actual 
clinical superiority of methylclonazepam over lorazepam 
is strongly suggested by the number of patients' preferences. 
Indeed, patients were asked to select which drug period 
they preferred and thus which treatment they would like 
to pursue and for which reason. Methylclonazepam was 
preferred by 11 patients (for only one preference favouring 
lorazepam), all of whom mentioned better anxiolytic activi- 
ty of the drug (associated in two cases with a better toler- 
ance). 
With regard to tolerance, the present study shows only 
a low rate of side-effects, all typical of benzodiazepine ther- 
apy, without any significant difference between compounds. 
However, the methodology used may lack adequate sensi- 
tivity for thorough and valid assessment of side-effects. 
Thus, patients using chronically high doses of benzodiaze- 
pine anxiolytics develop a high tolerance to their sedative 
properties (Aranko et al. 1983); moreover, inpatients do 
not have opportunity to assess drug effects on job perfor- 
mance and other activities. Accordingly, the clinical toler- 
ance of methyMonazepam and lerazepam needs to be com- 
pared in a separate study of anxious outpatients, for whom 
the selection criteria could be more flexible. 
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The final question is the extent to which the sample 
of  subjects included in the current  study is representative 
of  the general popula t ion  of  anxious patients who might 
benefit from benzodiazepine therapy.  In fact, most  benzo- 
diazepine anxiolytics are prescribed for mildly anxious out-  
patients over short  periods. The rate of  patients taking ben- 
zodiazepines for more than 1 year is low: about  15% of  
all anxiolytic users, according to a survey of  Mellinger et al. 
(1984), who suggest that  these patients tend to be older, 
most ly women, with high levels of  emotional  distress and 
chronic somatic health problems.  However,  in general, the 
most  efficient way to demonst ra te  clinical differences in 
therapeutic  activity is to start  with the subgroup having 
the highest severity of  illness. In  an analogous fashion, clini- 
cal studies of  ant idepressant  drugs are performed in severely 
depressed patients,  selected by r igorous criteria (such as 
Research Diagnost ic  Cri ter ia  for pr imary  or  endogenous 
depression), and often in hospital  settings; those patients 
represent a small fraction and specific subgroup of  all de- 
pressed patients treated with ant idepressant  drugs (Miller 
et al. 1983). The current s tudy supports  the value of  using 
a comparable  methodology  for the demonstra t ion of  clini- 
cal differences among anxiolytic agents. 
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